This piece first appeared December 23, 2006 in the Washington Times.
Pfizer's recent decision to terminate its 15,000-patient study of torcetrapib and abandon further development of this HDL-raising drug, while completely justified by the 60 percent increase in deaths among those taking it, casts a cloud over a whole class of cardiovascular therapeutics -- which is very bad news for millions of Americans at risk for heart disease.
This piece first appeared December 23, 2006 in the Washington Times.
Pfizer's recent decision to terminate its 15,000-patient study of torcetrapib and abandon further development of this HDL-raising drug, while completely justified by the 60 percent increase in deaths among those taking it, casts a cloud over a whole class of cardiovascular therapeutics -- which is very bad news for millions of Americans at risk for heart disease.